Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y.
Iwata H, et al. Among authors: chao c.
Breast Cancer Res Treat. 2019 Jan;173(1):123-133. doi: 10.1007/s10549-018-4964-y. Epub 2018 Sep 21.
Breast Cancer Res Treat. 2019.
PMID: 30242578
Free PMC article.
Clinical Trial.